Helping Science and Drug Development to Succeed through Pharma-Academia Partnerships
نویسندگان
چکیده
The theme of the 2013 Yale Healthcare Conference was "Partnerships in Healthcare: Cultivating Collaborative Solutions." The April conference brought together leaders across several sectors of health care, including academic research, pharmaceuticals, information technology, policy, and life sciences investing. In particular, the breakout session titled "Taking R&D Back to School: The Rise of Pharma-Academia Alliances" centered on the partnerships between academic institutions and pharmaceutical companies. Attendees of the session included members of the pharmaceutical industry, academic researchers, and physicians, as well as graduate and professional students. The discussion was led by Dr. Thomas Lynch of Yale University. Several topics emerged from the discussion, including resources for scientific discovery and the management of competing interests in collaborations between academia and the pharmaceutical industry.
منابع مشابه
Opening up the Ivory Tower
Big pharma is increasingly looking to academia for new drug leads and technologies; meanwhile universities are being forced to look beyond the National Institutes of Health (NIH) for funding. This mutual attraction-out-of-necessity is helping to forge new bonds between industry and academia.
متن کاملNext generation partnerships in translational science and medicine: Partnerships between academics, big pharma, biotech firms, philanthropists and patients look set to change the way science advances.
D uring graduation season, it is not uncommon for senior scientists to dispense wisdom from stages, lecterns, bus stops or bar stools. Nearly 50 years ago, in a memorable line from the 1967 movie, The Graduate, a single word of career advice is bestowed upon the film’s protagonist: plastics. For the biomedical graduate in 2015, another “p” word might be more appropriate: partnerships. Partnersh...
متن کاملLeveraging crowdsourcing to facilitate the discovery of new medicines.
Gloomy predictions about the future of pharma have forced the industry to investigate alternative models of drug discovery. Public-private partnerships (PPPs) have the potential to revitalize the discovery and development of first-in-class therapeutics. The new PPP Arch2POCM hopes to foster biomedical innovation through precompetitive validation of pioneer therapeutic targets for human diseases...
متن کاملPartnering with Big Pharma—What Academics Need to Know
Knowledge of the parameters of drug development can greatly aid academic scientists hoping to partner with pharmaceutical companies. Here, we discuss the three major pillars of drug development-pharmacodynamics, pharmacokinetics, and toxicity studies-which, in addition to pre-clinical efficacy, are critical for partnering with Big Pharma to produce novel therapeutics.
متن کاملReaping the benefits of biomedical research: partnerships required.
Reaping the benefits of investments in biomedical research can be achieved most efficiently through active collaboration among industry, academia, government, and nonprofit organizations. The National Institutes of Health (NIH) are exploring multiple ways in which to increase the efficiency of the translational process. Investigators involved in the NIH-funded Clinical and Translational Science...
متن کامل